コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ave limited therapeutic benefits in treating cholestatic liver disease.
2 rine when hepatic elimination is impaired by cholestatic liver disease.
3 vitamins is a major complication of chronic cholestatic liver disease.
4 latively common in children who have chronic cholestatic liver disease.
5 R agonists may be useful in the treatment of cholestatic liver disease.
6 s may prove useful in the treatment of human cholestatic liver disease.
7 cific instrument in ambulatory patients with cholestatic liver disease.
8 to be studied as potential therapeutics for cholestatic liver disease.
9 parenteral nutrition (TPN) with TPN-related cholestatic liver disease.
10 cid synthesis as a metabolic cause of severe cholestatic liver disease.
11 thanol (20% ethanol alone), and only 12% had cholestatic liver disease.
12 ents with primary biliary cirrhosis, another cholestatic liver disease.
13 Primary sclerosing cholangitis is a chronic cholestatic liver disease.
14 targets of systemic FXR agonist therapy for cholestatic liver disease.
15 d fibrotic responses in a BDL mouse model of cholestatic liver disease.
16 -like particle discovered from patients with cholestatic liver disease.
17 MC-derived TGF-B1 may be a target in chronic cholestatic liver disease.
18 sed by various etiologies and often leads to cholestatic liver disease.
19 (PSC) is a chronic inflammatory progressive cholestatic liver disease.
20 NHW in cases of hepatocellular carcinoma or cholestatic liver disease.
21 t that its targeting may be of relevance for cholestatic liver disease.
22 imary biliary cholangitis (PBC) is a chronic cholestatic liver disease.
23 e significant genetic burden contributing to cholestatic liver disease.
24 ificant causes of morbidity in children with cholestatic liver disease.
25 eptor (FXR); we here investigate its role in cholestatic liver disease.
26 ted here suggest that PHB1 is also linked to cholestatic liver disease.
27 which is frequently used in the treatment of cholestatic liver disease.
28 neficial use of fenofibrate therapy in human cholestatic liver disease.
29 itochondrial morphology has been observed in cholestatic liver disease.
30 tight-junction structure, leading to severe cholestatic liver disease.
31 therapeutic medications used in treatment of cholestatic liver disease.
32 ochondrial morphology to the pathogenesis of cholestatic liver disease.
33 , MDR3 is a potential therapeutic target for cholestatic liver disease.
34 d (TUDC), is a mainstay for the treatment of cholestatic liver disease.
35 ndings from genetic studies of patients with cholestatic liver disease.
36 the autoantibody production associated with cholestatic liver disease.
37 the formation of bile and the prevention of cholestatic liver disease.
38 were increased in livers from patients with cholestatic liver disease.
39 n the liver and prevent hepatocyte injury in cholestatic liver disease.
40 g colon cancer formation and progression and cholestatic liver disease.
41 fusion (IR) injury is frequently followed by cholestatic liver disease.
42 biting PAI-1 might attenuate liver injury in cholestatic liver diseases.
43 be a therapeutic antifibrogenic strategy in cholestatic liver diseases.
44 er clinical development for the treatment of cholestatic liver diseases.
45 ated with specific gene defects that lead to cholestatic liver diseases.
46 BECs) lining the hepatic bile ducts leads to cholestatic liver diseases.
47 polysaccharide (LPS) clearance is delayed in cholestatic liver diseases.
48 rs of CCA carcinogenesis and progression are cholestatic liver diseases.
49 ns for BA dysregulation of AdoR signaling in cholestatic liver diseases.
50 e liver-specific cell-death in patients with cholestatic liver diseases.
51 e for the maintenance of biliary mass during cholestatic liver diseases.
52 ial targets for pharmacological therapies of cholestatic liver diseases.
53 gies targeting BA transport and signaling in cholestatic liver diseases.
54 ary cholangitis (PBC) pathogenesis and other cholestatic liver diseases.
55 aling may be important for the management of cholestatic liver diseases.
56 rters and are natural targets for therapy of cholestatic liver diseases.
57 itus and painless jaundice that occur during cholestatic liver diseases.
58 r (FXR) and its potential therapeutic use in cholestatic liver diseases.
59 beticholic acid for the treatment of chronic cholestatic liver diseases.
60 DHEA-S levels was not seen in patients with cholestatic liver diseases.
61 et to modulate bile flow in the treatment of cholestatic liver diseases.
62 his review focuses on the recent advances in cholestatic liver diseases.
63 frequently the most debilitating symptom of cholestatic liver diseases.
64 dvance our understanding of the treatment of cholestatic liver diseases.
65 better understanding of the pathogenesis of cholestatic liver diseases.
66 better understanding of the pathogenesis of cholestatic liver diseases.
67 ur cohort of 28 MVID patients, 8 developed a cholestatic liver disease akin to progressive familial i
68 for cryptogenic, autoimmune, hepatitis B, or cholestatic liver disease and 91 non-liver transplantati
69 -alcoholic steatohepatitis, viral hepatitis, cholestatic liver disease and autoimmune liver diseases.
71 ing evidence supports an association between cholestatic liver disease and changes in the composition
72 ulation of bile acid homeostasis can lead to cholestatic liver disease and endoplasmic reticulum (ER)
73 e composition with important applications in cholestatic liver disease and gallstone disease, two ser
74 ry sclerosing cholangitis (PSC) is a chronic cholestatic liver disease and one of the most common ind
75 fects in patients with pruritus secondary to cholestatic liver disease and to assess the safety of lo
76 ligation (BDL) in the rat and in some human cholestatic liver diseases and is believed to ameliorate
77 langiocytes occurs during the progression of cholestatic liver diseases and is critical for the maint
78 igands may ameliorate human diseases such as cholestatic liver diseases and the associating acute ren
79 epidemiology, and treatment of a variety of cholestatic liver diseases and their associated complica
81 infants transplanted for reasons other than cholestatic liver disease, and patients transplanted bet
82 peutic indications in constipation, dry eye, cholestatic liver diseases, and inflammatory lung disord
83 malabsorption syndromes (especially owing to cholestatic liver disease), antibiotic therapy, and rena
87 from more diverse cohorts on autoimmune and cholestatic liver diseases are lacking, supporting the n
90 id (BA) homeostasis is an intrinsic facet of cholestatic liver diseases, but clinical usefulness of p
91 ression of many of these genes is altered in cholestatic liver diseases, but few have been extensivel
93 type 3 (PFIC3), an inherited juvenile-onset, cholestatic liver disease caused by homozygous mutation
94 The mice provide a novel animal model for cholestatic liver disease caused by TJP2-inactivating mu
95 Primary sclerosing cholangitis (PSC) is a cholestatic liver disease characterised by chronic infla
97 ry sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by biliary infla
98 itis (PSC) is an idiopathic and heterogenous cholestatic liver disease characterized by chronic infla
99 SC) is an idiopathic chronic immune-mediated cholestatic liver disease characterized by fibro-inflamm
100 rosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease characterized by progressive i
101 Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by strictures of
102 Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by strictures of
103 imary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destructi
104 imary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by the progressi
105 target of cholangiopathies that are chronic cholestatic liver diseases characterized by loss of prol
106 dents is often studied as an animal model of cholestatic liver disease, characterized by obstruction
107 heimer's disease (AD), Down's syndrome (DS), cholestatic liver disease (CLD) and abetalipoproteinemia
110 levated in neonates and children with severe cholestatic liver disease due to an autosomal recessive
111 diseases, including end-stage renal disease, cholestatic liver disease, endocrine/metabolic diseases,
112 sing cholangitis (PSC) is an immune-mediated cholestatic liver disease for which pharmacological trea
113 ary biliary cirrhosis (PBC) is a progressive cholestatic liver disease frequently leading to developm
116 centers with either autoimmune hepatitis or cholestatic liver disease had significantly lower risks
117 UDCA, a bile acid used in the treatment of cholestatic liver disease, has anti-inflammatory and cyt
119 alidity of risk stratification in autoimmune cholestatic liver disease, highlighting strengths and we
120 ited understanding of pruritus mechanisms in cholestatic liver diseases hinders development of antipr
121 ocrine phenotypes of cholangiocytes in human cholestatic liver diseases (ie, cholangiopathies) that a
123 ive genes previously known to be involved in cholestatic liver disease in British Bangladeshi and Pak
124 arbonyl-1,4-dihydrocollidine diet, to induce cholestatic liver disease in germ-free mice and germ-fre
126 r plasminogen activator inhibitor (PAI)-1 in cholestatic liver disease in mice suggested that tissue-
129 is, primary sclerosing cholangitis and other cholestatic liver diseases, in part, due to our incomple
130 lic acid (UDCA) is used for the treatment of cholestatic liver diseases including primary biliary cir
132 advances have been made in the treatment of cholestatic liver diseases, including primary biliary ci
133 eased awareness of PBC as a cause of chronic cholestatic liver disease is critical in evaluating non-
137 o-BEC conversion as a therapeutic option for cholestatic liver diseases, it will be important to thor
138 y biliary cholangitis (PBC) is an autoimmune cholestatic liver disease linked to symptoms including f
139 e, inflammatory bowel diseases, gastrectomy, cholestatic liver diseases, liver transplantation, and h
140 ta support the hypothesis that patients with cholestatic liver disease might benefit from UDCA with r
144 In the assessment of QOL in patients with cholestatic liver disease, NIDDK-QA is found reliable an
148 Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiolog
150 Primary sclerosing cholangitis is a chronic cholestatic liver disease of unknown origin that occurs
151 cation of modern investigative technologies, cholestatic liver diseases of genetic etiology are incre
154 ineural hearing loss, nystagmus, progressive cholestatic liver disease, pancreatic insufficiency, hyp
155 with HCV-negative patients, suggesting that cholestatic liver disease (particularly graft-versus-hos
156 In this review we develop the argument that cholestatic liver diseases, particularly primary biliary
159 l death that could benefit evaluation of the cholestatic liver diseases primary biliary cholangitis (
160 urthermore, nicotine may act as a mitogen in cholestatic liver disease processes, thereby facilitatin
161 ociated steatotic liver disease (MASLD), and cholestatic liver diseases, reducing the need for invasi
162 rd to the pathologic relevance of this work, cholestatic liver diseases represent a broad group of he
163 1950s as a clinical syndrome of progressive cholestatic liver disease resulting from chronic inflamm
164 tion, PCN risk was higher in recipients with cholestatic liver disease (SIR 2.78); five of these case
165 , 25% of patients undergoing OLT for chronic cholestatic liver disease still develop de novo fracture
167 ymptom commonly experienced by patients with cholestatic liver diseases such as primary biliary chola
168 ruritus is a common symptom in patients with cholestatic liver diseases such as primary biliary cirrh
169 but is believed to play an important role in cholestatic liver diseases such as primary familial intr
173 Primary biliary cholangitis is a chronic cholestatic liver disease that may progress to cirrhosis
174 erosing cholangitis (PSC) is a rare, chronic cholestatic liver disease that often progresses to end-s
175 liary cirrhosis (PBC) is an uncommon chronic cholestatic liver disease that primarily afflicts young
176 ry sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that progresses to death as a
177 and primary sclerosing cholangitis (PSC) are cholestatic liver diseases that have significant clinica
178 cholangitis (PSC) are infrequent autoimmune cholestatic liver diseases, that disproportionate to the
179 e the leading extrahepatic manifestations of cholestatic liver diseases, the mechanism underlying thi
182 eficiency of Mdr2 that progressively develop cholestatic liver disease, we investigated the contribut
183 an age at LTx was 9 months, the majority had cholestatic liver disease, were hospitalized pre-LTx, an
184 been primarily considered a manifestation of cholestatic liver disease, whereas this phenomenon is al
185 t-gut syndrome caused by volvulus and severe cholestatic liver disease who underwent simultaneous int